SCHEMBL3017002

SCHEMBL3017002

O=S(=O)(c1c(F)c(F)c(F)c(F)c1F)C1CCN(c2nc(Cc3ccc(F)c(Cl)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.35
SOS1 Q07889 7/20 0.34
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
AR P10275 3/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CACNA1G O43497 1/20 0.32
CACNA1H O95180 1/20 0.32
CACNA1I Q9P0X4 1/20 0.32
DNM1L O00429 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020062 0.93 L3MBTL1 (0.37) MAPTRAB9ASMN1; SMN2NPC1GAA
SCHEMBL3015392 0.93 PROKR1 (0.36) MAPTRAB9ASMN1; SMN2NPC1AR
SCHEMBL3021582 0.92 PKM (0.40) MAPTSOS1RAB9ASMN1; SMN2NPC1
SCHEMBL3016410 0.91 CACNA1G (0.37) MAPTRAB9ASMN1; SMN2NPC1AR
SCHEMBL3015850 0.90 MAPT (0.39) MAPTRAB9ASMN1; SMN2NPC1LMNA
SCHEMBL3009255 0.90 HTR2A (0.37) MAPTSOS1RAB9ASMN1; SMN2NPC1
SCHEMBL3017605 0.90 MAPT (0.35) MAPTSOS1RAB9ASMN1; SMN2NPC1
SCHEMBL3013010 0.89 MAPT (0.33) MAPTRAB9ASMN1; SMN2NPC1GAA
SCHEMBL3014605 0.89 SOS1 (0.38) MAPTSOS1ARTRPV1LMNA
SCHEMBL3012456 0.89 SOS1 (0.38) MAPTSOS1PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SOS1 715/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.